Surgeons have worked for years to innovate every step in the diagnosis and treatment plan for their cancer patients, with the ultimate goal of improving survivability and quality of life. Yet, intraoperative margin assessment remains one of their most pressing problems.
The S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. More information here.
With higher resolution than current technologies and unparalleled clarity for visualizing cellular-level disease, Perimeter S-Series OCT changes “let’s wait for pathology” to “let’s see right now.”
The images shown here depict the correlation between the real-time OCT volume and post-op pathology slides. It is clear to see that OCT captures detail that traditional imaging simply cannot provide.
Michele Carpenter, MD, FACS
Amelia Gunter, MD
Beth Anglin, MD, FACS
Shawndeep S. Tung, MD
Beth DuPree, MD, FACS, ABOIM
Amelia Tower, DO
The S-Series OCT has a general indication and has not been evaluated by FDA for specific uses. More information here.
Perimeter S-Series OCT can readily fit into surgeon’s existing workflow. The device itself is portable, so it can be moved to any OR that is being used when excising tissue. Scan times are 1-2 minutes per margin or about 15 minutes overall with interpretation. While OCT does not replace pathology, it provides essential real-time insight on margin status to give surgeons added assurance before closing.